Celularity ends role of chief commercial officer

Q: What executive change did Celularity (CELU) disclose on August 5, 2026?

Celularity disclosed that it terminated the employment of Rick Gonzalez, its Chief Commercial Officer, effective August 5, 2026. As of that date, Gonzalez ceased serving in the Chief Commercial Officer role at the company.

Q: Who signed the leadership change report on behalf of Celularity (CELU)?

The report documenting the leadership change was signed by K. Harold Fletcher, Celularity’s Chief Legal and Strategy Officer. He signed on behalf of Celularity, with a signature date of August 7, 2026, in his authorized corporate capacity.

Q: Where is Celularity (CELU) headquartered and what is its main contact number?

Celularity’s principal executive offices are at 170 Park Ave, Florham Park, New Jersey 07932. The company lists its main telephone number as (908) 768-2170, providing a primary point of contact for business and investor inquiries.

Celularity Inc. removed a key member of its senior leadership team.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Celularity Inc. removed a key member of its senior leadership team. On August 5, 2026, the company terminated the employment of Rick Gonzalez, who served as its Chief Commercial Officer, effective immediately. As of that date, he ceased serving in that role.

The report is executed on behalf of Celularity by K. Harold Fletcher, its Chief Legal and Strategy Officer. Celularity is incorporated in Delaware and maintains its principal executive offices at 170 Park Ave, Florham Park, New Jersey 07932.

Positive

None.

Negative

Termination of Chief Commercial Officer: Celularity ended the employment of its Chief Commercial Officer, Rick Gonzalez, effective August 5, 2026, creating an immediate vacancy in a senior commercial leadership role.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date of termination: August 5, 2026 Signature date: August 7, 2026 Main telephone number: (908) 768-2170

3 metrics

Effective date of termination August 5, 2026 Date Celularity terminated the employment of Chief Commercial Officer Rick Gonzalez

Signature date August 7, 2026 Date the report was signed by Chief Legal and Strategy Officer K. Harold Fletcher

Main telephone number (908) 768-2170 Registrant’s listed telephone number for Celularity’s principal executive offices

Key Terms

Emerging growth company, Section 12(b) of the Act, Chief Commercial Officer

3 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 12(b) of the Act regulatory

"Securities registered pursuant to Section 12(b) of the Act"

Chief Commercial Officer financial

"terminated the employment of Rick Gonzalez, the Company’s Chief Commercial Officer, effective immediately"

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Celularity (CELU) disclose on August 5, 2026?

Celularity disclosed that it terminated the employment of Rick Gonzalez, its Chief Commercial Officer, effective August 5, 2026. As of that date, Gonzalez ceased serving in the Chief Commercial Officer role at the company.

What role did Rick Gonzalez hold at Celularity (CELU) before his termination?

Before his termination, Rick Gonzalez served as Celularity’s Chief Commercial Officer. Celularity stated that his employment was terminated effective August 5, 2026, and that he ceased serving in this senior commercial leadership position on that date.

When did the termination of Rick Gonzalez’s employment at Celularity (CELU) become effective?

The termination of Rick Gonzalez’s employment at Celularity became effective August 5, 2026. Celularity noted that, as of that date, he ceased serving as the company’s Chief Commercial Officer, indicating an immediate leadership change.

Who signed the leadership change report on behalf of Celularity (CELU)?

The report documenting the leadership change was signed by K. Harold Fletcher, Celularity’s Chief Legal and Strategy Officer. He signed on behalf of Celularity, with a signature date of August 7, 2026, in his authorized corporate capacity.

Where is Celularity (CELU) headquartered and what is its main contact number?

Celularity’s principal executive offices are at 170 Park Ave, Florham Park, New Jersey 07932. The company lists its main telephone number as (908) 768-2170, providing a primary point of contact for business and investor inquiries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/07/2026 - 05:11 PM Accepted by SEC EDGAR 08/07/2026 - 05:10 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2026

Celularity Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38914

83-1702591

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

170 Park Ave

Florham Park, New Jersey

07932

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (908) 768-2170

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		CELU		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 5, 2026, Celularity Inc. (the “Company”) terminated the employment of Rick Gonzalez, the Company’s Chief Commercial Officer, effective immediately. As of such date, Mr. Gonzalez ceased serving as the Company’s Chief Commercial Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CELULARITY INC.
Dated: August 7, 2026
	By:	/s/ K. Harold Fletcher
	Name:	K. Harold Fletcher
	Title:	Chief Legal and Strategy Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents